Clinical trials: New Onset
Type 1 Diabetes Mellitus
Low Dose Cyclosporin and Methotrexate Therapy in Diabetes
The purpose of this study is to determine whether treatment with low dose cyclosporin and methotrexate can inhibit the development of new onset diabetes mellitus
- Trial name
- NCT00905073
- Testing
- cyclosporin and methotrexate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Georgetown University
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Diabetes Mellitus, Diabetes Mellitus, Type 1
Mesenchymal Stem Cells Transplantation in Newly Diagnosed Type-1 Diabetes Patients
Study Objects: Diabetes is an autoimmune disease which is mainly caused an immune reaction to beta cells in the pancreas. In this study, mesenchymal stem cells will be used for immune response modulation and improving…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Insulin-Dependent
- Trial name
- MSCTXT1DM (NCT04078308)
- Testing
- Intravenous Injection of autologous mesenchymal stem cells
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Royan Institute
Type 1 Diabetes (T1D)
PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study
This Phase 3, multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of SAB-142, a fully human anti-thymocyte globulin (h-ATG), in participants aged 5 to 40 years with…
- Trial name
- PRISE-hATG (NCT07670650)
- Testing
- SAB-142
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of Florida
Type 1 Diabetes, New Onset
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with…
- Trial name
- WAVE T1D (NCT07061574)
- Testing
- Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
- Where
- 11 sites in United States
- Volunteers
- 120 people
- Sponsor
- City of Hope Medical Center
Bowel Ischemia, Acute Bowel Ischemia / Infarction
Diagnosing Acute Onset Insufficient Intestinal Blood Flow (Bowel Ischemia) With a Novel CT Technique Called Dual-energy CT (DECT). This Observational Study Seeks to Evaluate Whether DECT Can Improve the Diagnosis of Bowel Ischemia and How the DECT Findings Correlate With Intraoperative Findings
The aim of this study is to evaluate the performance of dual-energy CT (DECT) in the diagnosis of acute bowel ischemia (ABI). ABI is a condition characterised by inadequate blood supply to portions of the intestine.
- Trial name
- NCT04561323
- Testing
- Dual-energy CT
- Where
- Denmark
- Volunteers
- 44 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Type 1 Diabetes
Effects of Vitamin D Supplementation in Subjects With New Onset of Type 1 Diabetes
In this placebo controlled study the investigators aim to investigate the effects of vitamin D supplementation in subjects with new onset of type 1 diabetes on immunological, endocrine and metabolic parameters.
- Trial name
- NCT01390480
- Testing
- Cholecalciferol
- Where
- Austria
- Volunteers
- 31 people
- Sponsor
- Medical University of Graz
Asthma, Lung Diseases
Air Pollution, Inflammation, and New Onset Asthma
To examine air pollution, inflammation and new onset asthma in a large cohort of children in southern California.
- Trial name
- NCT00241696
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
- Trial name
- NCT07222332
- Testing
- Baricitinib
- Where
- 130 sites in United States, Australia and 18 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Myopia
To Evaluate the Effectiveness of New Specially Designed Fitlens Soft Lens.
Myopia is a common disorder, affecting approximately one-third of the US population and over 90% of the population in some East Asian countries.
- Trial name
- NCT05433792
- Testing
- Myolens CN (Central-Near) soft contact lens, MiSight® soft contact lens
- Where
- Israel
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Fitlens Ltd.
Type 1 Diabetes
Microbiome in the Acute Stage of New Onset Paediatric Type 1 Diabetes
The goal of this observational study is to learn more about the microbiome and metabolome of children with type 1 diabetes (T1D). The main questions it aims to answer are: 1.
- Trial name
- NCT06157736
- Where
- Ireland
- Volunteers
- 100 people
- Sponsor
- University College Cork
Severe Aortic Valve Stenosis, High-degree AV Block
Infranodal Conduction Time During TAVR as Predictor of HAVB
Consecutive patients with high grade aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) with a self-expanding valve (Medtronic CoreValve Evolut R® or Edwards Sapien S3®) without pre-existing pacemaker…
- Conditions
- Severe Aortic Valve Stenosis, High-degree AV Block, Left Bundle-Branch Block
- Trial name
- HOM-TAVI (NCT04128384)
- Testing
- Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital, Saarland
Diabetes Mellitus, Type 1
New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
The objective of this study is to identify immune intervention strategies that will preserve residual beta cell function at the onset of type 1 diabetes.
- Trial name
- TN02 (NCT00100178)
- Testing
- Mycophenolate mofeteil (MMF), Daclizumab (DZB)
- Where
- 11 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Severe Hypoglycemia, Type1diabetes
Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes
The GLUREDIA study investigates the counter-regulatory response (CRR) during hypoglycemia in children with type 1 diabetes (T1D).
- Trial name
- GLUREDIA (NCT06770621)
- Testing
- Insulin-induced hypoglycemia test, Glucagon profile, Biological sample once
- Where
- Belgium
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Fever, Sweats, and Hot Flashes, Infection
Caspofungin Acetate in Treating Children With Fever and Neutropenia
RATIONALE: Giving caspofungin acetate may be effective in preventing or controlling fever and neutropenia caused by chemotherapy or bone marrow transplantation.
- Conditions
- Fever, Sweats, and Hot Flashes, Infection, Kidney Cancer, Leukemia
- Trial name
- NCT00020527
- Testing
- caspofungin acetate
- Where
- 5 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Prematurity, Infections, NIRS
The Peripheral(-Muscle) Oxygenation and Perfusion Score as a New Non-invasive Tool to Predict Elevations in C-reactive Protein Levels in Neonates
This is a prospective, single-center Phase II observational study investigating the predictive value of the "Peripheral(-muscle) Oxygenation and Perfusion Score" (POP-Score), a novel non-invasive composite index, for early…
- Conditions
- Prematurity, Infections, NIRS, Near Infrared Spectroscopy, Preterm Neonates
- Trial name
- POP-Score (NCT07109856)
- Testing
- POP-Score Assessment, Near-Infrared Spectroscopy (NIRS)
- Where
- Austria
- Volunteers
- 93 people
- Sponsor
- Medical University of Graz
Retinal Dystrophies
SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)
The goal of this observational study is to utilize a novel imaging system designed for high-resolution retinal imaging of neonates, infants and children to identify the signs of photoreceptor development and degeneration in…
- Trial name
- SS-HH-OCT (NCT06177977)
- Testing
- SS-HH-OCT
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Duke University
Atrial Fibrillation, Coronary Artery Disease
Management of New-Onset Postoperative Atrial Fibrillation
One common occurrence following open heart surgery is an irregular rhythm from the top chambers of the heart known as atrial fibrillation (afib or AF).
- Conditions
- Atrial Fibrillation, Coronary Artery Disease, Post Operative Arrythmia
- Trial name
- Monitor-AF (NCT01395836)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 1
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100…
- Trial name
- NCT05743244
- Testing
- Abrocitinib 200 MG Oral Tablet, Ritlecitinib
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 78 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Crohn's Disease
High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children
The purpose of this 4 week study is to determine whether PASER®, an approved delayed-release oral formulation of 4-aminosalicylic acid, in doses of 50 milligrams per kilogram three times daily for 2 weeks followed by 50…
- Trial name
- NCT00495521
- Testing
- 4-Aminosalicylic acid extended release granules
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Jacobus Pharmaceutical